Equities

Eom Pharmaceutical Holdings Inc

IMUC:PKL

Eom Pharmaceutical Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.124
  • Today's Change0.045 / 56.76%
  • Shares traded1.11k
  • 1 Year change-55.71%
  • Beta0.3978
Data delayed at least 15 minutes, as of Sep 20 2024 18:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Eom Pharmaceutical Holdings Inc share price to rise to 5.00 in the next year from the last price of 0.124.
High3,932.3%5.00
Med3,932.3%5.00
Low3,932.3%5.00

Earnings history & estimates in USD

Earnings forecasts are not available for Eom Pharmaceutical Holdings Inc. On Mar 13, 2018, Eom Pharmaceutical Holdings Inc reported 4th quarter 2017 losses of -- per share.
Annual earnings information is not available for Eom Pharmaceutical Holdings Inc.
Average growth rate-8.42%
More ▼

Revenue history & estimates in USD

ImmunoCellular Therapeutics, Ltd. did not report revenues for the 4th quarter 2017. However, during the 4th quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
ImmunoCellular Therapeutics, Ltd. did not report revenues for the full year 2017. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.